BOBULSKY SUSAN 4

What Happened

• Susan Bobulsky, Chief Commercial Officer of Adaptive Biotechnologies (ADPT), sold 5,000 shares in an open-market transaction on June 11, 2026. The shares were disposed at $19.00 each for total gross proceeds of $95,000. This was a sale (not a purchase), which is often routine insider selling.

Key Details

• Transaction date: 2026-06-11
• Transaction type: Sale (open market) — 5,000 shares at $19.00 each
• Total proceeds: $95,000 (gross)
• Footnote: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025
• Shares owned after transaction: Not specified in the provided filing excerpt
• Filing: Form 4 filed with accession 0001820885-26-000010 on 2026-06-15; the filing itself does not indicate a late-report flag

Context

• Sales under a 10b5-1 plan are pre-arranged trades and are typically executed according to a formula or schedule set when the plan was established; they do not necessarily reflect the insider’s current view of the company. This summary is factual and does not speculate on motivations.